LLY
Eli Lilly
$1.18Tn
1,252.10
+3.41%
+51.48%
Eli Lilly discovers, develops, manufactures, and markets branded prescription drugs across therapeutic areas such as cardiometabolic health, oncology, immunology, and neuroscience. Its revenue is primarily generated from the sale of branded pharmaceutical products like insulin analogs and GLP-1 receptor agonists.
JNJ
Johnson & Johnson
$610.67Bn
253.40
-0.21%
+32.55%
The company's Innovative Medicine segment generates significant revenue from branded prescription pharmaceuticals such as STELARA, TREMFYA, and XARELTO. These products are sold to retailers, wholesalers, and hospitals for the treatment of oncology, immunology, and cardiovascular diseases.
ABBV
AbbVie
$500.71Bn
283.35
-0.06%
+25.25%
AbbVie is a diversified pharmaceutical company that develops and markets branded prescription drugs across multiple therapeutic areas. Its revenue is driven by branded products such as Vraylar, Ubrelvy, Qulipta, and Mavyret.
MRK
Merck
$358.60Bn
145.35
-1.36%
+72.81%
Merck's primary revenue driver is the sale of branded prescription pharmaceuticals and vaccines for human health, with 2025 pharmaceutical sales totaling $58,142 million. Key branded products cited include Keytruda, Gardasil, and Januvia.
NVS
Novartis Ag
$286.95Bn
150.38
+2.36%
+15.70%
Novartis is an innovative medicines company that researches, develops, manufactures, and markets branded prescription pharmaceuticals across therapeutic areas such as cardiovascular, renal, metabolic diseases, immunology, neuroscience, and oncology. Its primary revenue is generated from the sale of these pharmaceutical products to wholesalers, health systems, and government agencies.
AZN
Astrazeneca
$258.32Bn
166.66
+2.84%
-1.77%
AstraZeneca is a global biopharmaceutical company that discovers, develops, and markets branded prescription medicines. Its revenue is primarily driven by the sale of branded pharmaceutical products such as Tagrisso, Farxiga, and Symbicort across various therapeutic areas.
GILD
2nd
Gilead Sciences
$195.30Bn
157.37
+2.49%
+33.03%
Gilead develops and markets branded prescription small-molecule antiviral drugs for HIV and hepatitis, such as Biktarvy, Descovy, and Epclusa.
PFE
Pfizer
$167.74Bn
29.43
+0.72%
+20.66%
Pfizer is a global biopharmaceutical company that discovers, develops, and markets a vast portfolio of branded prescription drugs and vaccines, including Eliquis, Prevnar, and Paxlovid. Its primary revenue is generated from the sale of these branded pharmaceutical products to hospitals, patients, and healthcare providers.
VRTX
2nd
Vertex Pharmaceuticals
$128.89Bn
508.75
+2.06%
+24.72%
Vertex develops and manufactures branded small-molecule prescription drugs, such as its cystic fibrosis modulators (e.g., TRIKAFTA) and the oral pain inhibitor JOURNAVX.
BMY
Bristol Myers Squibb
$123.73Bn
60.57
+2.18%
+38.89%
Bristol Myers Squibb is a large pharmaceutical firm that discovers, develops, and markets a wide portfolio of branded prescription medicines such as Eliquis, Sprycel, and Abraxane. Its revenue is primarily generated from the sale of these innovative branded pharmaceuticals across multiple therapeutic areas.
GSK
Gsk
$105.79Bn
49.03
+2.40%
+11.99%
GSK is a global biopharmaceutical company that discovers, develops, and markets branded prescription drugs across multiple therapeutic areas. Its revenue is primarily derived from the sale of branded products such as Dovato, Cabenuva, and Nucala.
TAK
Takeda Pharmaceutical
$61.93Bn
19.46
+2.31%
+40.40%
Takeda is a global pharmaceutical company that develops and markets branded prescription drugs across multiple therapeutic areas. Its revenue is driven by branded products such as ENTYVIO for inflammatory bowel disease and VYVANSE for ADHD.
SNY
Sanofi
$49.13Bn
40.29
+1.31%
-17.71%
Sanofi is a global pharmaceutical company that discovers, develops, and markets branded prescription drugs across multiple therapeutic areas. Its revenue is primarily derived from the sale of branded medicines such as Dupixent for immunology and Sarclisa for oncology.
TEVA
2nd
Teva Pharmaceutical Industries
$47.92Bn
41.12
+0.93%
+107.89%
The company develops and sells patented innovative medicines such as AUSTEDO, AJOVY, UZEDY, and COPAXONE for neurological and oncological indications.
ONC
BeOne Medicines
$42.28Bn
374.08
+6.43%
+18.32%
BeOne Medicines discovers, develops, and markets branded prescription drugs for oncology, specifically hematology and solid tumors. Its primary revenue is derived from the sales of branded medicines such as BRUKINSA and TEVIMBRA.
RVMD
Revolution Medicines
$40.55Bn
189.26
-2.20%
+281.88%
Revolution Medicines is a clinical-stage company developing small-molecule RAS(ON) inhibitors for cancers such as pancreatic ductal adenocarcinoma and non-small cell lung cancer. Its core business is the discovery and development of branded prescription pharmaceuticals based on its proprietary tri complex technology platform.
ALC
2nd
Alcon
$32.45Bn
66.58
+4.23%
-10.01%
Alcon develops and markets branded prescription pharmaceuticals for ocular health, including Rocklatan and Rhopressa for the treatment of glaucoma.
GEHC
2nd
GE HealthCare Technologies
$31.78Bn
70.35
+2.75%
-3.92%
The Pharmaceutical Diagnostics segment develops and sells branded prescription pharmaceuticals, specifically contrast media and radiopharmaceutical imaging agents used in radiology and nuclear medicine.
ROIV
2nd
Roivant Sciences
$24.60Bn
34.04
+1.25%
+100.35%
The company also develops branded small-molecule prescription drugs, such as brepocitinib (a TYK2/JAK1 inhibitor) developed through its Priovant subsidiary.
UTHR
United Therapeutics
$23.11Bn
541.51
+0.27%
+25.29%
The company's primary revenue is derived from the sale of branded prescription pharmaceuticals for pulmonary hypertension and oncology, specifically Tyvaso DPI, Remodulin, Orenitram, and Unituxin.
INCY
Incyte
$22.76Bn
113.27
+1.52%
+28.50%
Incyte is a biopharmaceutical company that discovers, develops, and markets branded prescription drugs such as JAKAFI, ICLUSIG, and OPZELURA. Its revenue is primarily derived from the sale of these branded pharmaceutical products to specialty pharmacies, hospital pharmacies, and wholesalers.
INSM
2nd
Insmed
$21.66Bn
99.21
+1.45%
-39.34%
Insmed also develops small-molecule branded prescription drugs, such as brensocatib, a small molecule inhibitor of dipeptidyl peptidase 1 for the treatment of hidradenitis suppurativa.
VTRS
2nd
Viatris
$20.93Bn
18.22
+4.47%
+82.57%
The company maintains a significant portfolio of branded products, including those protected by patent or marketed as branded generics, which contribute a significant portion of its sales.
EXEL
Exelixis
$15.64Bn
62.83
+3.02%
+56.96%
Exelixis focuses on the discovery, development, and commercialization of branded prescription oncology medicines, specifically small molecule tyrosine kinase inhibitors. Its primary revenue is generated from the net product sales of branded drugs such as CABOMETYX and COMETRIQ.
JAZZ
Jazz Pharmaceuticals
$13.92Bn
214.42
+2.28%
+57.89%
Jazz Pharmaceuticals develops and markets branded prescription drugs for rare diseases, including Xywav for sleep disorders, Epidiolex for epilepsies, and Zepzelca for oncology. Its revenue is primarily generated through net product sales of these specialized, branded medications.
NBIX
Neurocrine Biosciences
$13.91Bn
136.95
+0.77%
-0.57%
Neurocrine Biosciences develops and markets branded prescription drugs, with the vast majority of its revenue coming from the sale of INGREZZA for tardive dyskinesia and CRENESSITY for congenital adrenal hyperplasia. These are branded small-molecule pharmaceuticals sold through specialty pharmacies and wholesale distributors.
BWXT
2nd
BWX Technologies
$12.57Bn
137.23
+2.08%
-32.67%
The company produces and sells radiopharmaceuticals and medical radioisotopes to hospitals and pharmaceutical firms for diagnostic and therapeutic applications.
FMS
2nd
Fresenius Medical Care AG
$12.35Bn
22.11
+2.60%
-16.94%
The company develops and markets renal pharmaceuticals, specifically mentioning erythropoietin stimulating agents, iron sucrose, and phosphate binders.
CORT
Corcept Therapeutics
$12.26Bn
113.37
-2.46%
+47.60%
Corcept Therapeutics discovers, develops, and markets branded prescription drugs, specifically its lead product Korlym for the treatment of hypercortisolism. Its revenue is generated from the sale of these branded pharmaceuticals to physicians and healthcare providers.
GKOS
2nd
Glaukos
$9.75Bn
165.70
-1.26%
+93.57%
The company develops and commercializes branded pharmaceutical products, such as the iDose TR intracameral pharmaceutical implant and iLink therapies for corneal crosslinking. These branded prescription therapies represent a material portion of the company's revenue and product pipeline.
KYMR
Kymera Therapeutics
$8.95Bn
108.14
+1.23%
+71.95%
Kymera Therapeutics develops oral small molecule medicines, such as those targeting STAT6, IRF5, IRAK4, and CDK2, which are branded prescription pharmaceuticals. The company's core business is the discovery and development of these small-molecule drugs to treat immune inflammatory diseases and oncology.
CYTK
Cytokinetics
$8.89Bn
63.92
+0.77%
+1.78%
Cytokinetics develops and markets branded prescription drugs, specifically the oral small molecule inhibitor MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy. Its revenue is generated from the sales of these branded pharmaceuticals and associated licensing milestones.
AXSM
Axsome Therapeutics
$8.46Bn
161.79
-0.27%
+24.86%
Axsome is a fully integrated biopharmaceutical company that manufactures and markets branded prescription drugs, including AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness, and SYMBRAVO for migraine. Its core revenue stream comes from the sale of these branded pharmaceutical products in the United States.
PRAX
2nd
Praxis Precision Medicines
$6.93Bn
248.24
+3.86%
+332.85%
The company also develops small molecule therapies through its Cerebrum platform, including candidates like ulixacaltamide and relutrigine for which it has submitted New Drug Applications (NDAs).
ALKS
Alkermes
$6.72Bn
40.10
+2.61%
+24.42%
Alkermes develops and markets branded prescription drugs for neuroscience disorders, including ARISTADA, LYBALVI, VIVITROL, and LUMRYZ. Its primary revenue is generated through the direct sales of these proprietary branded pharmaceuticals.
AMRX
2nd
Amneal Pharmaceuticals
$6.15Bn
19.25
+1.85%
+96.83%
The Specialty segment generates revenue from branded prescription pharmaceuticals for central nervous system and endocrine disorders, specifically citing products like CREXONT®, RYTARY®, UNITHROID®, and Brekiya®.
BLTE
Belite Bio
$6.00Bn
152.62
-0.07%
+87.82%
Belite Bio is a clinical-stage company developing branded prescription drugs, specifically oral small molecules like tinlarebant (LBS 008) and LBS 009. These candidates target therapeutic areas such as Stargardt disease, geographic atrophy, and metabolic disorders like type 2 diabetes.
BLCO
2nd
Bausch & Lomb
$5.96Bn
16.69
+3.99%
+11.49%
The company develops and markets branded prescription eye medications for conditions like glaucoma and dry eye, specifically citing products such as MIEBO, XIIDRA, and Vyzulta.
TVTX
Travere Therapeutics
$4.97Bn
52.79
-0.90%
+96.61%
Travere Therapeutics develops and markets branded prescription drugs for rare kidney and metabolic diseases, such as FILSPARI (sparsentan) for IgAN and Thiola for cystinuria. Its revenue is primarily generated from the sales of these branded pharmaceutical products.
AMRN
Amarin Corp Plc\Uk
$4.86Bn
11.57
-0.34%
-42.06%
Amarin is a pharmaceutical company that develops and markets branded prescription drugs, specifically its flagship product VASCEPA (icosapent ethyl). Its revenue is primarily generated from the sale of this branded pharmaceutical to wholesalers and through licensing agreements with commercial collaborators.
MANE
Veradermics
$4.80Bn
114.86
+1.49%
—
Veradermics is developing VDPHL01, an oral extended-release formulation of minoxidil, which is a branded prescription drug for pattern hair loss. The company intends to generate revenue from prescriptions written by dermatologists and primary care physicians.
GPCR
Structure Therapeutics
$4.74Bn
22.19
+1.42%
-24.08%
Structure Therapeutics is a biopharmaceutical company focused on discovering and developing oral small molecule therapeutics, such as aleniglipron (a GLP1R agonist) and amylin receptor agonists. Because its pipeline consists of small-molecule drugs rather than biologics, it fits the Pharmaceuticals classification.
RGC
Regencell Bioscience Holdings
$4.72Bn
9.52
+17.39%
-49.25%
Regencell Bioscience Holdings focuses on the research, development, and commercialization of a standardized Traditional Chinese Medicine (TCM) formula for the treatment of ADHD and ASD. The company intends to generate revenue from the sale of these branded pharmaceutical products once they receive regulatory approval.
ERAS
2nd
Erasca
$4.65Bn
14.87
+1.16%
+497.19%
In addition to biologics, the company develops small molecule therapeutics, including the pan RAS molecular glue (ERAS 0015) and the pan KRAS inhibitor (ERAS 4001), which fall under branded pharmaceutical development.
EWTX
Edgewise Therapeutics
$4.12Bn
38.20
+3.19%
+144.56%
Edgewise Therapeutics focuses on discovering and developing small molecule therapies, such as sevasemten and EDG-7500, for muscle diseases. Because its pipeline consists of small-molecule drug candidates rather than biologics, it fits the Pharmaceuticals classification.
INDV
Indivior Pharmaceuticals
$3.97Bn
33.62
-1.58%
+33.47%
Indivior develops and markets branded prescription pharmaceuticals, specifically SUBLOCADE and SUBOXONE Film, for the treatment of opioid use disorder. Its revenue is derived from the sale of these branded medications to healthcare providers, pharmacies, and distributors.
DFTX
Definium Therapeutics
$3.79Bn
34.26
+0.06%
+170.62%
Definium Therapeutics is developing branded prescription drugs for brain health disorders, specifically DT120 (lysergide d tartrate) and DT402 (R enantiomer of MDMA). These are small-molecule pharmaceutical compounds targeting generalized anxiety disorder, major depressive disorder, and autism spectrum disorder.
OGN
Organon
$3.62Bn
13.77
+0.22%
+44.19%
Organon's primary revenue comes from the sale of branded prescription pharmaceuticals, specifically its Women's Health segment featuring products like Nexplanon and NuvaRing. The company markets these branded medicines across therapeutic areas including contraception, fertility, and cardiovascular health.
ACAD
Acadia Pharmaceuticals
$3.39Bn
19.71
+2.39%
-9.34%
Acadia Pharmaceuticals develops and markets branded prescription drugs, specifically NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome. Its revenue is derived almost exclusively from the net product sales of these branded pharmaceuticals.
LQDA
Liquidia
$3.10Bn
34.78
+2.47%
+50.17%
Liquidia develops and markets branded prescription drugs for respiratory and vascular conditions, specifically its lead commercial product YUTREPIA. Revenue is primarily derived from the sale of this branded pharmaceutical to patients and healthcare providers.
TARS
Tarsus Pharmaceuticals
$3.07Bn
70.99
-1.80%
-5.28%
Tarsus Pharmaceuticals develops and markets branded prescription drugs, specifically XDEMVY lotilaner ophthalmic solution for the treatment of Demodex blepharitis. The company generates the majority of its revenue from the sales of this branded pharmaceutical product to eye care professionals and patients.
DNLI
2nd
Denali Therapeutics
$2.93Bn
18.34
+2.63%
+12.45%
The company also pursues small molecule programs, such as LRRK2 inhibitors for Parkinson's disease, which falls under the development of branded prescription pharmaceuticals.
RCUS
2nd
Arcus Biosciences
$2.90Bn
22.84
+1.38%
+35.15%
In addition to antibodies, the company develops small molecule therapies, such as the HIF-2α inhibitor casdatifan and the CD73 inhibitor vemliclustat, which fall under branded pharmaceutical development.
ELVN
Enliven Therapeutics
$2.88Bn
39.33
+0.13%
+80.99%
Enliven Therapeutics is a clinical-stage company focused on the discovery and development of small molecule therapeutics, such as ELVN-001 for chronic myeloid leukemia and ELVN-002 for HER2 inhibition. These are branded prescription drug candidates rather than biologics, placing the company in the Pharmaceuticals category.
ZLAB
2nd
Zai Lab
$2.64Bn
23.51
+4.49%
-20.01%
The company also commercializes branded prescription small-molecule pharmaceuticals, such as QINLOCK for gastrointestinal stromal tumors and AUGTYRO for non-small cell lung cancer.
NRIX
2nd
Nurix Therapeutics
$2.59Bn
24.95
+5.41%
+141.06%
The company develops small molecule degrader drugs, such as bexobrutideg and zelebrudomide, which are branded prescription drug candidates for the treatment of cancer and inflammatory diseases.
NAMS
NewAmsterdam Pharma
$2.43Bn
20.62
+3.05%
-49.02%
NewAmsterdam Pharma is developing obicetrapib, a branded prescription drug for cardiometabolic diseases and Alzheimer's. The company plans to commercialize this small-molecule CETP inhibitor independently in the US and via licensing in Europe, generating revenue from direct sales, milestone payments, and royalties.
BHC
2nd
Bausch Health Companies
$2.36Bn
6.32
+7.30%
+4.98%
The company develops and markets branded prescription pharmaceuticals, specifically citing the Xifaxan product line within its Salix segment.
SUPN
Supernus Pharmaceuticals
$2.30Bn
39.57
-1.52%
-19.69%
Supernus Pharmaceuticals develops and markets branded prescription drugs for CNS diseases, such as Qelbree for ADHD and ZURZUVAE for postpartum depression. Its revenue is primarily generated from the sale of these proprietary branded pharmaceuticals to wholesalers and specialty pharmacies.
SLS
2nd
SELLAS Life Sciences
$2.29Bn
11.34
-4.55%
+420.18%
In addition to its peptide immunotherapy, the company is developing SLS009, which is described as a highly selective small molecule inhibitor of cyclin dependent kinase 9.
HRMY
Harmony Biosciences Holdings
$2.22Bn
38.27
+2.03%
+43.71%
Harmony Biosciences discovers, develops, and markets branded prescription drugs for rare neurological diseases, with the vast majority of its revenue coming from the sale of its branded product WAKIX (pitolisant). The company's business model is centered on branded pharmaceutical sales to specialty pharmacies and distributors.
AUPH
Aurinia Pharmaceuticals
$2.22Bn
16.73
+0.72%
+45.86%
Aurinia Pharmaceuticals develops and markets branded prescription drugs, specifically its flagship oral therapy LUPKYNIS for lupus nephritis. The company generates the majority of its revenue from the direct sale of this branded pharmaceutical product in the U.S. and through royalties and supply agreements internationally.
CURLF
2nd
Curaleaf Holdings
$2.21Bn
8.35
-2.11%
-16.50%
Curaleaf operates pharma-grade manufacturing facilities in Europe (Germany, Spain, Canada, Portugal, and the UK) that produce cannabinoid-based pharmaceutical products for medical use.
BCRX
2nd
Biocryst Pharmaceuticals
$2.05Bn
8.02
-0.37%
+17.77%
The company also develops and markets branded small-molecule prescription drugs, most notably ORLADEYO (berotralstat), an oral therapy for the prevention of hereditary angioedema attacks.
IMNM
2nd
Immunome
$1.97Bn
17.40
+1.16%
+6.42%
The company also develops small-molecule inhibitors, such as the oral gamma secretase inhibitor varegacestat, which falls under the development of branded prescription pharmaceuticals.
MLYS
Mineralys Therapeutics
$1.91Bn
21.64
+4.24%
-50.08%
Mineralys Therapeutics is developing lorundrostat, an oral aldosterone synthase inhibitor, which is a branded prescription drug candidate for hypertension and cardiorenal conditions. The company's core business is the discovery and development of this small-molecule pharmaceutical to treat diseases driven by dysregulated aldosterone.
PVLA
Palvella Therapeutics
$1.83Bn
127.34
+3.88%
+66.87%
Palvella Therapeutics is a biopharmaceutical company developing branded prescription topical therapies, such as QTORIN rapamycin and QTORIN pitavastatin, for rare skin diseases. These are small-molecule active ingredients (rapamycin and pitavastatin) formulated into gels, fitting the profile of branded pharmaceutical development.
XERS
Xeris Biopharma Holdings
$1.75Bn
10.07
+3.07%
+8.63%
Xeris Biopharma develops and markets branded prescription drugs such as Recorlev for Cushing's syndrome, Gvoke for severe hypoglycemia, and Keveyis for Primary Periodic Paralysis. Its revenue is generated through the sale of these branded pharmaceutical products to patients via healthcare provider prescriptions.
BHVN
2nd
Biohaven
$1.73Bn
11.44
+4.76%
-34.10%
The company also develops small-molecule pharmacological approaches, such as the Kv7 ion channel modulation platform for opakalim (BHV-7000) used in epilepsy and depressive disorders.
TRVI
Trevi Therapeutics
$1.72Bn
12.11
+0.41%
+14.03%
Trevi Therapeutics is a clinical-stage company developing Haduvio (oral nalbuphine ER), which is a small-molecule branded prescription drug candidate for chronic cough. The company's focus is on the discovery and development of this branded pharmaceutical therapy for patients with idiopathic pulmonary fibrosis and refractory cough.
ANIP
2nd
Ani Pharmaceuticals
$1.72Bn
72.28
+3.02%
-19.78%
The company operates a 'Rare Disease and Brands' segment that commercializes branded prescription drugs such as Cortrophin Gel, ILUVIEN, and YUTIQ, as well as a portfolio including Atacand and Arimidex.
NUVB
Nuvation Bio
$1.64Bn
4.74
+1.28%
+25.73%
Nuvation Bio develops and markets branded prescription oncology drugs, specifically the FDA-approved IBTROZI for ROS1 positive non small cell lung cancer. Its revenue is generated through direct product sales in the US and licensing/royalties from partners like Eisai and Nippon Kayaku.
ZBIO
2nd
Zenas BioPharma
$1.61Bn
25.40
+2.17%
-5.89%
In addition to its biologics, the company is developing orelabrutinib, which is described as an oral BTK inhibitor, representing a small-molecule pharmaceutical development program.
INVA
Innoviva
$1.52Bn
20.86
-0.52%
+19.95%
Innoviva develops and commercializes a portfolio of branded prescription therapeutics for critical care and infectious diseases, including GIAPREZA, XACDURO, XERAVA, and ZEVTERA. It also earns significant revenue from branded respiratory products developed in collaboration with GSK.
RARE
2nd
Ultragenyx Pharmaceutical
$1.50Bn
15.17
+1.81%
-54.62%
In addition to biologics, the company's product modalities include small molecules, which are used to develop branded prescription drugs for rare indications.
ETON
Eton Pharmaceuticals
$1.45Bn
51.33
-2.93%
+168.04%
Eton Pharmaceuticals develops and markets branded prescription drugs for rare diseases, such as INCRELEX for insulin-like growth factor 1 deficiency and GALZIN for Wilson disease. Its revenue is derived from the sale of these branded pharmaceutical products to healthcare providers and patients.
PCRX
Pacira BioSciences
$1.45Bn
36.33
-0.19%
+54.93%
The company's primary revenue is derived from branded prescription pharmaceuticals, specifically EXPAREL (a long-acting local analgesic) and ZILRETTA (an extended-release corticosteroid), which together account for the vast majority of its total revenue.
AAPG
2nd
Ascentage Pharma Group International
$1.36Bn
14.55
-2.02%
-60.56%
The company develops and markets branded prescription drugs, such as Olverembatinib and Lisaftoclax, which are sold to hospitals and pharmacies for the treatment of leukemia and other blood cancers.
OMER
2nd
Omeros
$1.35Bn
18.79
+1.95%
+80.33%
In addition to biologics, the company develops small molecule therapeutics, such as the PDE7 inhibitor OMS527 and MASP 2/3 small molecule inhibitors, which fall under branded pharmaceutical development.
OPK
Opko Health
$1.20Bn
1.61
+17.52%
+5.92%
The company develops, manufactures, and markets branded prescription drugs such as the growth hormone NGENLA and the kidney disease treatment Rayaldee. It generates significant revenue from direct sales of these branded pharmaceuticals and royalty payments from partners like Pfizer.
HROW
Harrow
$1.08Bn
28.75
+5.54%
-27.10%
Harrow develops and markets a wide range of FDA-approved branded ophthalmic pharmaceuticals, such as IHEEZO, VEVYE, and VIGAMOX. Its primary revenue is generated from the sale of these branded prescription products for conditions like dry eye and glaucoma.
LBRX
Lb Pharmaceuticals
$1.05Bn
36.69
+7.91%
+122.09%
Lb Pharmaceuticals is developing LB 102, a branded prescription drug candidate for neuropsychiatric disorders like schizophrenia and bipolar depression. The company expects future revenue from the commercial sale of oral and long-acting injectable formulations of this branded pharmaceutical to healthcare providers and patients.
KURA
Kura Oncology
$862.85Mn
9.70
+0.94%
-5.73%
Kura Oncology discovers, develops, and markets branded prescription small-molecule therapeutics, specifically the FDA-approved drug KOMZIFTI for the treatment of NPM1-mutated AML. Its revenue is derived from the commercial sale of this branded pharmaceutical product.
VSTM
Verastem
$835.15Mn
9.23
+19.71%
-1.81%
Verastem discovers, develops, and markets branded prescription drugs, specifically the AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer. Its revenue is derived principally from the sales of this branded pharmaceutical product in the United States.
CRVS
2nd
Corvus Pharmaceuticals
$828.59Mn
9.85
+5.01%
+28.09%
The company also develops small molecule inhibitors, such as the oral ITK inhibitor soquelitinib and the adenosine A2A receptor antagonist ciforadenant, which fall under branded pharmaceutical development.
SGP
SpyGlass Pharma
$826.79Mn
24.72
+4.35%
—
SpyGlass Pharma is a biopharmaceutical company developing branded prescription drug delivery systems, specifically the BIM IOL System and BIM DRS, to treat glaucoma and ocular hypertension using the drug bimatoprost. Its revenue model is based on the sale of these branded pharmaceutical products and associated reimbursement for the physician-administered drug component.
AVBP
2nd
ArriVent BioPharma
$811.29Mn
16.79
+3.64%
-18.42%
The company is developing firmonertinib, a tyrosine kinase inhibitor (TKI), which is a small-molecule branded prescription drug candidate for non-small cell lung cancer.
COLL
Collegium Pharmaceutical
$753.31Mn
23.18
+2.98%
-29.50%
Collegium develops and markets branded prescription drugs, including Jornay PM for ADHD and Xtampza ER for pain management. Its revenue is generated from the sale of these branded pharmaceutical products to wholesale distributors.
LXRX
Lexicon Pharmaceuticals
$737.34Mn
1.65
+3.12%
+7.84%
Lexicon is a biopharmaceutical company that discovers, develops, and markets branded prescription drugs, specifically commercializing INPEFA for heart failure. Its revenue is derived from the sales of this branded pharmaceutical product and licensing agreements for other small-molecule drug candidates.
ACHV
Achieve Life Sciences
$715.94Mn
6.97
-0.43%
+119.18%
Achieve Life Sciences is a specialty pharmaceutical company developing cytisinicline, a branded prescription drug for the treatment of nicotine dependence. The company's business model is centered on the development and future commercialization of this branded pharmaceutical product.
GYRE
Gyre Therapeutics
$678.62Mn
6.40
-1.08%
-27.85%
Gyre Therapeutics is a commercial-stage company that develops and markets branded small-molecule prescription drugs. Its revenue is driven by the sale of branded therapies such as ETUARY® (pirfenidone), Etorel® (nintedanib), and Contiva® (avatrombopag).
DSGN
Design Therapeutics
$655.84Mn
10.48
+7.71%
+56.18%
Design Therapeutics is a clinical-stage company developing GeneTAC molecules, which it explicitly describes as a 'novel class of small molecule' therapeutics. Because its core platform focuses on small-molecule drug discovery for branded prescription use (targeting diseases like Friedreich ataxia and Huntington's disease) rather than biologics, it fits the Pharmaceuticals category.
MNPR
2nd
Monopar Therapeutics
$613.35Mn
71.80
-1.78%
-20.59%
The company is developing ALXN1840, a small-molecule oral drug for the treatment of Wilson disease, which falls under the category of branded prescription pharmaceuticals.
ZVRA
Zevra Therapeutics
$609.44Mn
10.27
+0.39%
-12.82%
Zevra Therapeutics develops and markets branded prescription drugs for rare diseases, specifically MIPLYFFA for Niemann-Pick disease type C and OLPRUVA for urea cycle disorders. Its revenue is derived from the sale of these branded pharmaceutical products through specialty pharmacy distribution channels.
IVA
Inventiva
$600.97Mn
3.11
+8.36%
-43.14%
Inventiva is a clinical-stage company developing lanifibranor, which is described as an oral small molecule therapy. Because the lead candidate is a small-molecule drug rather than a biologic, it fits the Pharmaceuticals category for branded prescription drug development.
OLMA
Olema Pharmaceuticals
$600.80Mn
6.87
+1.03%
-33.75%
Olema Pharmaceuticals is a clinical-stage company developing novel small molecule therapeutics, such as palazestrant and OP-3136, for breast cancer. Its business model focuses on the discovery, development, and eventual commercialization of branded prescription drugs.
PHAT
Phathom Pharmaceuticals
$600.53Mn
7.50
+1.35%
-44.24%
Phathom Pharmaceuticals develops and markets branded prescription drugs, specifically VOQUEZNA, VOQUEZNA DUAL PAK, and VOQUEZNA TRIPLE PAK for gastrointestinal diseases. Its revenue is generated solely from the sale of these branded pharmaceutical products in the United States.
CRMD
CorMedix
$579.40Mn
7.46
+0.95%
-29.69%
CorMedix develops and markets branded prescription pharmaceuticals, most notably DefenCath, an FDA-approved antimicrobial catheter lock solution. The company also sells a portfolio of branded anti-infective agents such as REZZAYO and VABOMERE, and the cardiovascular product TOPROL XL.
DCTH
2nd
Delcath Systems
$512.96Mn
14.81
+0.61%
+30.83%
The company markets the HEPZATO KIT, which is a drug/device combination involving the delivery of chemotherapy (melphalan) for the treatment of uveal melanoma liver metastases, and holds orphan drug designations for its therapies.
AQST
Aquestive Therapeutics
$509.58Mn
4.06
-11.93%
-44.69%
Aquestive Therapeutics is a pharmaceutical company that develops and markets branded prescription drugs, such as Libervant for epilepsy rescue. Its business model focuses on creating alternative administration methods for complex molecules to replace standard of care therapies.
NVCT
Nuvectis Pharma
$505.33Mn
18.93
+5.17%
+210.84%
Nuvectis Pharma is a clinical-stage company developing small molecule drug candidates, specifically NXP900, which is a targeted small molecule inhibitor of SRC and YES1 kinases. Because its lead candidates are small-molecule drugs rather than biologics, it fits the Pharmaceuticals classification for branded prescription drug development.
EOLS
Evolus
$499.72Mn
7.57
+4.85%
+14.52%
Evolus develops and markets branded prescription products for aesthetic use, specifically Jeuveau (a botulinum toxin) and Evolysse (hyaluronic acid gels). These are branded pharmaceutical products sold to licensed aesthetic practitioners for the treatment of frown lines and wrinkles.
ACRS
2nd
Aclaris Therapeutics
$487.99Mn
3.49
+3.25%
+80.83%
In addition to biologics, the company develops covalent small molecule inhibitors targeting pathways such as ITK, which falls under the discovery and development of branded prescription pharmaceuticals.
SVA
2nd
Sinovac Biotech
$464.94Mn
6.47
+0.00%
—
The company develops and markets a broad portfolio of branded prescription vaccines for human infectious diseases, including those for pneumococcal disease (PnuPreve) and tetanus, serving both government-funded programs and private-pay markets.
OVID
Ovid Therapeutics
$417.55Mn
2.26
+3.20%
+36.97%
Ovid Therapeutics is a biopharmaceutical company focused on discovering and developing small molecule medicines, such as the GABA aminotransferase inhibitor OV329, to treat brain disorders. Its business model targets the development of branded prescription pharmaceuticals for indications including epilepsy, psychosis, and neuropsychiatric manifestations.
ANL
2nd
Adlai Nortye
$415.13Mn
12.09
+11.12%
+628.31%
In addition to biologics, the company develops branded small-molecule prescription drugs for oncology, such as the oral pan RAS(ON) inhibitor AN9025 and the oral PD-L1 inhibitor AN4005.
SPRY
ARS Pharmaceuticals
$404.71Mn
4.07
+3.56%
-62.90%
ARS Pharmaceuticals develops and markets neffy, a branded prescription intranasal epinephrine spray for the emergency treatment of anaphylaxis. Revenue is generated from the sale of this branded pharmaceutical product to wholesalers and pharmacies.
OCS
2nd
Oculis Holding AG
$386.60Mn
7.40
+3.21%
-65.36%
The company is also developing OCS 01 (a dexamethasone formulation) and Privosegtor (a peptoid small molecule), which are branded small-molecule pharmaceutical candidates.
EBS
Emergent BioSolutions
$368.33Mn
7.18
+4.06%
-25.21%
The company develops, manufactures, and markets branded prescription drugs and vaccines, including NARCAN Nasal Spray, anthrax vaccines, and smallpox vaccines. Its primary revenue is derived from the sale of these commercial and medical countermeasure products to government agencies and healthcare providers.
MPLT
MapLight Therapeutics
$364.40Mn
8.02
+2.69%
—
MapLight Therapeutics is a biopharmaceutical company developing branded prescription drug candidates for CNS disorders, such as ML-007C-MA for schizophrenia and Alzheimer's disease psychosis. Its pipeline consists of small-molecule agonists and antagonists, such as the M1/M4 muscarinic agonist and the GPR52 positive allosteric modulator ML-009.
NIKA
Nika Pharmaceuticals
$359.20Mn
0.41
+0.00%
-14.58%
The company develops and distributes branded prescription medicinal products, specifically Thymus Nuclear Glycoprotein for HIV treatment and products based on the Inactivated Pepsin Fraction platform. These are sold to hospitals and healthcare providers for the treatment of patients.
TTRX
Turn Therapeutics
$345.24Mn
11.59
+4.32%
+127.25%
Turn Therapeutics is primarily focused on developing GX-03, a non-biologic topical immunomodulator for moderate-to-severe eczema and onychomycosis. This activity constitutes the company's core drug development segment and targets the branded prescription pharmaceutical market.
VTVT
vTv Therapeutics
$342.37Mn
27.59
+0.25%
+23.11%
vTv Therapeutics focuses on developing orally administered small-molecule therapies, such as the liver selective glucokinase activator cadisegliatin and a PDE4 inhibitor. These are branded prescription drug candidates targeting metabolic and inflammatory diseases like type 1 and type 2 diabetes.
IRD
2nd
Opus Genetics
$334.72Mn
4.05
-1.22%
+102.50%
The company also develops and licenses small-molecule branded pharmaceuticals, such as Phentolamine Ophthalmic Solution for presbyopia and APX3330 for diabetic retinopathy. It generates significant revenue from the licensing of Phentolamine to Viatris.
XFOR
X4 Pharmaceuticals
$333.55Mn
2.64
+7.76%
-7.69%
X4 Pharmaceuticals develops and markets branded prescription drugs, specifically the small-molecule oral antagonist XOLREMDI (mavorixafor) for the treatment of WHIM syndrome. Its revenue is derived from the sale of this branded pharmaceutical product and associated licensing and royalty payments.
IKT
Inhibikase Therapeutics
$319.47Mn
1.83
+1.67%
+14.38%
Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing IKT-001, an oral prodrug of imatinib, which is a small-molecule branded prescription drug candidate for pulmonary arterial hypertension.
SWKHL
2nd
SWK Holdings
$303.85Mn
25.12
-0.04%
-2.10%
The company has a dedicated Pharmaceutical Development segment that engages in the development, manufacturing, and licensing of pharmaceutical compounds and drug delivery systems, such as its collaboration with Aptar.
AGMB
2nd
AgomAb Therapeutics
$284.61Mn
8.33
-4.14%
—
The company is also developing small-molecule branded prescription drugs, specifically the oral ALK5 inhibitor ontunisertib (AGMB-129) for FSCD and the inhaled ALK5 inhibitor AGMB-447 for IPF.
FULC
Fulcrum Therapeutics
$279.97Mn
3.67
+0.00%
-61.93%
Fulcrum Therapeutics is a clinical-stage company developing branded prescription small molecules, specifically its lead candidate pociredir for the treatment of sickle cell disease. The company's core business is the discovery and development of small-molecule drugs to treat genetically defined rare diseases.
PALI
Palisade Bio
$267.34Mn
1.54
+4.05%
-10.98%
Palisade Bio is a clinical-stage biopharmaceutical company developing PALI-2108, a small-molecule oral phosphodiesterase-4 (PDE4) inhibitor prodrug. Its business model focuses on the discovery and development of branded prescription pharmaceuticals for inflammatory bowel disease, specifically ulcerative colitis and Crohn's disease.
PRLD
2nd
Prelude Therapeutics
$264.95Mn
3.32
+2.79%
+144.12%
The company also develops small-molecule inhibitors, such as the mutant-selective JAK2 inhibitor PRT12396, which falls under the development of branded prescription pharmaceuticals.
VNDA
Vanda Pharmaceuticals
$256.33Mn
4.24
+0.47%
-21.19%
Vanda Pharmaceuticals develops and markets branded prescription drugs such as Fanapt for schizophrenia and PONVORY for multiple sclerosis. Its revenue is generated primarily from the sale of these branded pharmaceutical products to wholesalers and specialty pharmacies.
IMRX
Immuneering
$235.50Mn
3.64
+6.43%
-40.91%
Immuneering is a clinical oncology company developing branded prescription anti-cancer medicines, specifically its lead product candidate atebimetinib, an oral MEK inhibitor. The company's core business is the discovery and development of a novel class of medicines called Deep Cyclic Inhibitors.
SIGA
Siga Technologies
$228.44Mn
3.19
+2.90%
-62.11%
SIGA Technologies is a commercial-stage pharmaceutical company that develops and markets TPOXX (tecovirimat), a branded prescription antiviral drug. Its revenue is derived from the sale of this branded pharmaceutical to the U.S. government (BARDA and Department of Defense) and foreign health agencies.
EVMN
2nd
Evommune
$215.15Mn
5.93
+3.13%
—
The company is also developing EVO756, which is described as an oral small molecule antagonist, fitting the profile of a branded prescription pharmaceutical developer.
SLGL
Sol-Gel Technologies
$191.41Mn
68.70
-1.15%
+64.51%
Sol-Gel develops and markets branded prescription topical treatments for dermatology, specifically Twyneo for acne vulgaris and Epsolay for rosacea. The company generates revenue from these branded products through licensing agreements, royalties, and milestone payments from partners like Mayne Pharma.
AKBA
Akebia Therapeutics
$190.22Mn
0.70
+0.00%
-76.27%
Akebia Therapeutics develops and commercializes branded prescription drugs for kidney disease, specifically Vafseo for anemia and Auryxia for phosphorus control. Its revenue is primarily generated from the sale of these branded pharmaceuticals in the United States.
SION
Sionna Therapeutics
$184.27Mn
4.08
-0.24%
-86.80%
Sionna Therapeutics is a clinical-stage company developing small molecule therapies, such as SION-719 and SION-451, to treat cystic fibrosis. These drug candidates are designed as branded prescription pharmaceuticals targeting the CFTR protein's nucleotide binding domain 1.
ACOG
Alpha Cognition
$183.99Mn
8.45
-2.31%
+16.87%
Alpha Cognition develops, manufactures, and markets ZUNVEYL, a branded prescription oral tablet for the treatment of mild to moderate Alzheimer's disease. Revenue is generated from the commercial sale of this branded pharmaceutical product through wholesalers and pharmacies.
ZNTL
Zentalis Pharmaceuticals
$160.54Mn
2.24
-3.45%
+40.88%
Zentalis is a clinical-stage company developing azenosertib, which is described as an oral small molecule inhibitor of the WEE1 kinase. Because it is developing a branded small-molecule pharmaceutical for oncology rather than a biologic, it fits the Pharmaceuticals category.
MENS
Jyong Biotech
$150.53Mn
1.98
-3.41%
-96.60%
Jyong Biotech is a biopharmaceutical company that discovers, develops, and manufactures branded prescription drugs such as Botreso® for benign prostatic hyperplasia and PCP for prostate cancer prevention. Its revenue model is based on the commercialization of these proprietary drug candidates and licensing agreements.
DERM
Journey Medical
$140.77Mn
5.12
-3.03%
-31.82%
Journey Medical is a commercial-stage pharmaceutical company that sells and markets FDA-approved branded prescription drugs for dermatological conditions, such as Emrosi, Qbrexza, and Accutane. Its revenue is primarily generated from the sale of these branded pharmaceutical products.
LONA
LeonaBio
$125.51Mn
5.29
-1.86%
+42.59%
LeonaBio is a biopharmaceutical company developing small molecule candidates, specifically lasofoxifene for metastatic breast cancer and ATH 1105 for ALS. These are branded prescription drug candidates rather than biologics, fitting the description of Pharmaceuticals.
FTH
2nd
Faeth Therapeutics
$116.25Mn
20.60
+3.00%
+50.58%
The company's lead product candidate, PIKTOR, is described as an oral multi node inhibitor, which is a small-molecule branded prescription drug candidate for endometrial and breast cancer.
CRDL
Cardiol Therapeutics
$115.30Mn
1.15
+0.88%
+6.48%
Cardiol Therapeutics is a clinical-stage company developing small molecule drug candidates, specifically CardiolRx and CRD 38, for the treatment of inflammatory heart diseases like pericarditis and myocarditis. These are branded prescription pharmaceutical candidates targeting specific therapeutic areas.
NERV
Minerva Neurosciences
$114.29Mn
2.42
+2.98%
-3.59%
Minerva Neurosciences is a clinical-stage biopharmaceutical company developing roluperidone, a branded prescription drug candidate for the treatment of schizophrenia. The company's business model focuses on the discovery and development of proprietary small-molecule product candidates for central nervous system diseases.
SPRB
2nd
Spruce Biosciences
$114.16Mn
41.47
+6.39%
-73.93%
The company also develops small-molecule drugs, such as tildacerfont, a CRF1 receptor antagonist for the treatment of major depressive disorder.
CPIX
Cumberland Pharmaceuticals
$112.97Mn
7.54
+0.67%
+119.19%
Cumberland Pharmaceuticals focuses on the acquisition, development, and commercialization of branded prescription pharmaceuticals. It generates revenue from the sale of FDA-approved branded products such as Acetadote, Caldolor, and Vibativ.
LENZ
LENZ Therapeutics
$112.16Mn
3.57
+4.08%
-91.47%
LENZ Therapeutics is a commercial pharmaceutical company that develops and markets VIZZ (aceclidine ophthalmic solution), a branded prescription drug for treating presbyopia. Its revenue is derived from the sale of this branded pharmaceutical product and associated international licensing and royalty agreements.
VXRT
2nd
Vaxart
$111.70Mn
0.46
+0.00%
+31.43%
The company earns royalty revenue from the net sales of branded antiviral products, Relenza and Inavir, paid by pharmaceutical companies GlaxoSmithKline and Daiichi Sankyo.
TNXP
Tonix Pharmaceuticals Holding
$107.81Mn
6.42
+0.31%
-67.08%
Tonix Pharmaceuticals is a fully-integrated company that discovers, develops, and markets branded prescription drugs. It generates revenue from the sale of FDA-approved branded products such as TONMYA for fibromyalgia and Zembrace SymTouch and Tosymra for acute migraine.
IFRX
2nd
InflaRx
$104.10Mn
1.44
-2.70%
+15.20%
The company is developing izicopan, which is described as an orally administered small molecule inhibitor of the C5a receptor for chronic autoimmune and inflammatory conditions.
VANI
Vivani Medical
$102.82Mn
1.15
-0.86%
-12.88%
Vivani Medical is a clinical-stage biopharmaceutical company developing branded drug implant candidates, specifically focusing on GLP1 receptor agonists for obesity and type 2 diabetes. Its primary business model is the development and potential commercialization of these branded prescription therapies.
UPC
Universe Pharmaceuticals
$96.71Mn
4.09
-1.45%
-32.51%
The company manufactures and markets its own branded traditional Chinese medicine (TCMD) products, such as Bai Nian Dan and Hu Zhuo Ren, targeting chronic conditions and cold/flu. Revenue is primarily generated from the sale of these proprietary branded pharmaceutical formulas.
ELOX
Eloxx Pharmaceuticals
$93.01Mn
13.70
+12.20%
—
Eloxx Pharmaceuticals is a clinical-stage company developing small molecule therapeutics, such as exaluren, to treat rare kidney diseases. Its revenue model is based on branded pharmaceutical development, including licensing agreements with partners like Almirall, S A for the development of ZKN 013.
TNYA
2nd
Tenaya Therapeutics
$91.93Mn
0.41
+5.13%
-78.42%
In addition to its gene therapy pipeline, the company is advancing a small molecule program, TN-301, which is a selective HDAC6 inhibitor intended for heart failure and other indications.
PYPD
2nd
PolyPid
$89.20Mn
4.90
+1.45%
+46.27%
The company's lead product candidate, D-PLEX 100, utilizes the FDA-approved antibiotic doxycycline, a branded pharmaceutical agent, to prevent surgical site infections.
SMNR
Semnur Pharmaceuticals
$85.18Mn
0.37
+0.00%
-95.89%
Semnur Pharmaceuticals is developing SP-102, a branded prescription injectable formulation of dexamethasone sodium phosphate for the treatment of sciatica. The company's business model is centered on the discovery, development, and potential commercialization of this branded pharmaceutical product.
AARD
Aardvark Therapeutics
$84.47Mn
3.86
-0.52%
-72.29%
Aardvark Therapeutics is a biopharmaceutical company developing novel small molecule therapeutics, such as ARD-101 and ARD-201, for the treatment of metabolic diseases. These are branded prescription drug candidates targeting Bitter Taste Receptors (TAS2Rs) for conditions like Prader Willi syndrome and obesity.
TENX
Tenax Therapeutics
$76.81Mn
1.51
-1.31%
-78.37%
Tenax Therapeutics is a development-stage pharmaceutical company focused on branded prescription therapies for pulmonary hypertension. Its lead product candidates, levosimendan (TNX-103) and imatinib, are small-molecule drugs being developed for commercial sale to healthcare providers and patients.
PTHS
Pelthos Therapeutics
$75.86Mn
20.40
+0.20%
-26.17%
Pelthos Therapeutics develops and markets branded prescription drugs, specifically ZELSUVMI, XEPI, and XEGLYZE. Its primary revenue is generated from the sale of these FDA-approved branded pharmaceutical products through distribution channels.
MNOV
Medicinova
$71.37Mn
1.45
-1.36%
+16.94%
Medicinova is developing oral small molecule therapeutics, specifically MN 166 and MN 001, for indications such as multiple sclerosis and glioblastoma. These are branded prescription drug candidates rather than biologics, fitting the description of pharmaceutical discovery and development.
NTHI
Neonc Technologies Holdings
$71.32Mn
2.75
+3.38%
-74.63%
NeOnc is a biopharmaceutical company developing branded prescription drug candidates, specifically NEO100 and NEO212, for the treatment of intracranial malignancies and Parkinson's disease. Its business model focuses on the discovery and clinical development of these small-molecule compounds derived from perillyl alcohol.
CGTX
Cognition Therapeutics
$69.39Mn
0.73
-6.41%
-60.11%
Cognition Therapeutics is a clinical-stage company developing zervimesine (CT1812), which is explicitly described as an orally delivered small molecule therapeutic. The company's core business is the discovery and development of branded prescription small-molecule drugs for Alzheimer's disease and dementia with Lewy bodies.
PMVP
PMV Pharmaceuticals
$68.96Mn
1.29
+4.03%
-10.42%
PMV Pharmaceuticals focuses on the discovery and development of small molecule therapies, such as its lead candidate rezatapopt, to treat p53-related cancers. The company's revenue model is based on the future sales of these branded prescription pharmaceuticals and potential licensing agreements.
VRCA
Verrica Pharmaceuticals
$64.94Mn
3.78
-1.31%
-7.80%
Verrica Pharmaceuticals develops and markets branded prescription drugs for dermatologic diseases, specifically its lead product YCANTH for molluscum contagiosum. Revenue is generated from the sales of this branded pharmaceutical product to healthcare providers.
FBIO
2nd
Fortress Biotech
$63.62Mn
1.91
+0.53%
-32.27%
The company generates significant revenue from branded prescription pharmaceuticals through Journey Medical Corporation, which markets FDA-approved dermatology products such as Emrosi, Qbrexza, and Accutane.
CING
Cingulate
$61.00Mn
4.39
-3.94%
+9.75%
Cingulate is a biopharmaceutical company developing branded prescription drugs for ADHD and anxiety, such as CTx-1301 (dexmethylphenidate) and CTx-2103 (buspirone). Its revenue model is based on the development and commercialization of these branded pharmaceutical products.
BMEA
Biomea Fusion
$60.89Mn
0.84
+1.20%
-49.09%
Biomea Fusion is a clinical-stage company developing oral small molecule drugs, specifically icovamenib and BMF650, for diabetes and obesity. These are branded prescription drug candidates based on synthetic chemistry rather than biological science.
PLRX
Pliant Therapeutics
$60.06Mn
0.97
+10.23%
-38.22%
Pliant Therapeutics is developing small molecule inhibitors, such as its lead candidate PLN-101095, which is described as an oral, small molecule dual inhibitor. Since the company focuses on branded small-molecule drug discovery and development for oncology indications, it fits the Pharmaceuticals classification.
VERU
Veru
$56.24Mn
2.44
+14.55%
-44.42%
Veru is a biopharmaceutical company developing branded prescription drugs, specifically enobosarm for obesity and sabizabulin for atherosclerotic cardiovascular disease. These are small-molecule oral medicines (a selective androgen receptor modulator and a microtubule disruptor) intended for branded pharmaceutical sales.
AIFC
2nd
AI Financial
$54.54Mn
0.39
-2.50%
-83.82%
The Biotechnology segment is dedicated to developing and commercializing non-opioid therapies for chronic pain, specifically mentioning drug candidates JAN101 and JAN123.
BOLD
Boundless Bio
$52.82Mn
2.35
-1.67%
+78.03%
Boundless Bio is a clinical-stage oncology company developing small molecule drugs to inhibit targets in ecDNA biology. Its pipeline consists of ecDNA directed therapeutic candidates intended for patients with oncogene amplified cancers such as breast and gastric cancer.
ANVS
Annovis Bio
$45.16Mn
1.06
+3.92%
-41.44%
Annovis Bio is developing buntanetap, which is described as an orally administered small molecule designed to treat Alzheimer's and Parkinson's disease. The company's focus on small-molecule drug discovery and development for branded prescription use aligns with the Pharmaceuticals industry.
APLM
2nd
Apollomics
$44.32Mn
20.18
-7.30%
+3.49%
The company also develops small-molecule tumor inhibitors, such as the lead candidate vebreltinib (a selective cMet inhibitor) and APL-102, which fall under branded pharmaceutical development.
CLNN
Clene
$42.30Mn
3.31
+0.00%
-62.77%
Clene is a clinical-stage pharmaceutical company developing branded prescription therapeutics such as CNM-Au8 for the treatment of neurodegenerative diseases like ALS, MS, and Parkinson's. Its core business model is the discovery, development, and potential commercialization of these novel nanotechnology-based drugs.
IXHL
Incannex Healthcare
$36.13Mn
2.88
+0.70%
-74.80%
Incannex Healthcare is a clinical-stage biopharmaceutical company developing oral fixed-dose combination therapies, such as IHL-42X for sleep apnea and PSX-001 for anxiety. These are described as combinations of active agents (small molecules) rather than biologics, fitting the profile of a branded pharmaceutical developer.
GOSS
Gossamer Bio
$35.56Mn
8.89
-0.11%
-95.39%
Gossamer Bio is a biopharmaceutical company developing seralutinib, an inhaled small molecule inhibitor, for the treatment of pulmonary arterial hypertension. Its revenue model is based on collaboration agreements, such as the one with Chiesi, and potential future sales of these branded prescription drugs.
APRE
Aprea Therapeutics
$33.16Mn
0.62
+6.90%
-58.39%
Aprea Therapeutics focuses on the discovery and development of small molecule inhibitors, such as the WEE1 inhibitor APR-1051 and the ATR inhibitor ATRN-119. These are branded prescription drug candidates designed for oncology patients with biomarker-defined cancers.
GRCE
Grace Therapeutics
$31.73Mn
1.95
+3.17%
-37.30%
Grace Therapeutics is a biopharmaceutical company developing branded prescription drug candidates for rare diseases such as aneurysmal subarachnoid hemorrhage and ataxia telangiectasia. Its business model focuses on the development and commercialization of these branded therapies via the 505(b)(2) regulatory pathway.
UG
United Guardian
$31.47Mn
6.85
-1.72%
-6.80%
The company's largest revenue stream (51%) comes from pharmaceutical products, specifically Renacidin, which is an FDA-approved drug for preventing and dissolving urethral catheter calcifications.
MCUJF
Medicure
$30.58Mn
2.93
-1.68%
+275.64%
Medicure develops, manufactures, and markets branded prescription cardiovascular drugs, specifically AGGRASTAT for acute coronary syndrome and ZYPITAG for hyperlipidemia. These products are sold to drug wholesalers for distribution to hospitals and pharmacies.
NSRX
Nasus Pharma
$28.49Mn
3.16
-0.63%
-60.00%
Nasus Pharma is a clinical-stage pharmaceutical company developing branded prescription drugs, specifically NS002 (intranasal epinephrine) and NS001 (intranasal naloxone). Its business model is based on the future sale of these proprietary, branded pharmaceutical products for emergency medical conditions.
CPHI
China Pharma Holdings
$28.37Mn
0.70
+2.94%
-63.16%
The company develops, manufactures, and markets branded prescription pharmaceuticals such as Candesartan tablets for hypertension and Gastrodin Injection for cerebrovascular support. These products are sold through distributors to state-owned hospitals.
ATOS
Atossa Therapeutics
$26.45Mn
2.65
-4.68%
-83.17%
Atossa Therapeutics is developing Z endoxifen, which is described as an oral small molecule acting as a selective estrogen receptor modulator and degrader. The company's focus is on branded prescription medicines for oncology and rare diseases, fitting the profile of a pharmaceutical developer of small-molecule drugs.
BETRF
2nd
BetterLife Pharma
$24.30Mn
0.16
-5.88%
+220.00%
The company also develops small-molecule pharmaceutical candidates for neuropsychiatric indications, such as BETR-001 (a non-hallucinogenic LSD derivative) and BETR-002 (a formulation of dihydrohonokiol).
BYSI
BeyondSpring
$23.85Mn
0.58
-4.92%
-64.85%
BeyondSpring is a biopharmaceutical company focused on developing Plinabulin, which is described as a first-in-class small molecule microtubule modulator. Its pipeline consists of small-molecule oncology programs (BPI-002, BPI-003, BPI-004) and targeted protein degradation molecules via its interest in SEED Therapeutics.
CRVO
CervoMed
$23.05Mn
2.25
-1.75%
-72.22%
CervoMed is developing neflamapimod, which is explicitly described as an orally administered, small-molecule drug candidate. The company's primary business is the discovery and development of branded prescription pharmaceuticals for neurodegenerative diseases like dementia with Lewy bodies.
TXMD
TherapeuticsMD
$22.34Mn
1.93
-2.03%
+85.58%
TherapeuticsMD holds patents and trademarks for branded prescription drugs in women's healthcare, specifically hormone therapy and contraceptive solutions like IMVEXXY, BIJUVA, and ANNOVERA. Although it now operates as a royalty company, its core business is the ownership and monetization of branded pharmaceutical assets.
AYTU
Aytu Biopharma
$21.84Mn
2.01
+3.08%
-13.36%
Aytu Biopharma discovers, develops, and markets branded prescription drugs, specifically focusing on CNS diseases. Its primary revenue is generated from the sale of branded therapeutics such as EXXUA for major depressive disorder and Adzenys for ADHD.
SCLX
Scilex Holding
$19.84Mn
2.82
-1.05%
-68.39%
Scilex Holding develops and markets branded prescription drugs for pain management, specifically ZTlido for postherpetic neuralgia, ELYXYB for acute migraine, and GLOPERBA for gout prophylaxis. Revenue is generated from the sales of these branded pharmaceutical products to wholesalers and healthcare providers.
MDBH
2nd
MDB Capital Holdings
$19.16Mn
1.86
-5.58%
-51.05%
Through MDB Minnesota One Inc, the company is developing a small molecule anti-senescence platform consisting of pharmaceutical drugs aimed at promoting longevity and inhibiting age-related diseases.
PTN
2nd
Palatin Technologies
$18.35Mn
6.49
-12.53%
-9.10%
In addition to peptides, the company develops small-molecule agonists and antagonists for the treatment of obesity and metabolic related disorders, which falls under branded pharmaceutical development.
INTI
Inhibitor Therapeutics
$17.38Mn
0.10
+25.00%
+100.00%
Inhibitor Therapeutics is a pharmaceutical development company focused on creating and commercializing branded therapeutics for oncology and rare diseases, specifically using itraconazole for basal cell carcinoma nevus syndrome, prostate cancer, and lung cancer. Its business model relies on future branded product sales, milestone payments, and royalties.
YARW
Yarrow Bioscience
$17.16Mn
20.00
+5.82%
+5.54%
VYNE Therapeutics is a biopharmaceutical company developing small molecule BET inhibitors, specifically repibresib gel (VYN201) and VYN202. These are branded prescription drug candidates targeting inflammatory and immune-mediated conditions like vitiligo and plaque psoriasis.
MIRA
Mira Pharmaceuticals
$15.64Mn
0.66
-2.94%
-50.00%
Mira Pharmaceuticals is a clinical-stage pharmaceutical development company focusing on branded prescription drug candidates. Its pipeline includes an oral ketamine analog for neuropathic pain and an oral pharmaceutical marijuana molecule for dementia and anxiety.
KPRX
Kiora Pharmaceuticals
$14.76Mn
2.39
-3.24%
-12.13%
Kiora Pharmaceuticals is a clinical-stage pharmaceutical company developing branded prescription therapies such as KIO 301 for retinitis pigmentosa and KIO 104 for retinal inflammatory diseases. Its business model focuses on the discovery and development of small-molecule drugs, including a photoswitch molecule and a dihydroorotate dehydrogenase inhibitor.
KAPA
2nd
Kairos Pharma
$13.95Mn
0.67
-9.46%
-92.34%
In addition to antibodies, the company is developing small molecule drug candidates aimed at treating prostate, lung, breast, and glioblastoma cancers.
NCEL
NewcelX
$13.43Mn
2.80
+7.28%
-83.53%
NewcelX is a biopharmaceutical company developing branded prescription drugs, specifically lead compounds like Quilience and Nolazol (mazindol), for the treatment of narcolepsy and ADHD. Its business model focuses on the discovery, development, and potential commercialization of new chemical entities and repurposed molecules.
ALLR
Allarity Therapeutics
$13.21Mn
0.83
-4.60%
-44.67%
Allarity Therapeutics is a pharmaceutical company focused on developing novel anti-cancer therapeutics, specifically its lead candidate stenoparib, a dual inhibitor of PARP1/2 and tankyrases. The company's primary business objective is the clinical development and potential commercialization of these branded prescription drugs for patients with ovarian and small cell lung cancer.
ANEB
Anebulo Pharmaceuticals
$12.74Mn
0.31
+0.00%
-87.40%
Anebulo Pharmaceuticals is developing selonabant, a small molecule CB1 antagonist, which is a branded prescription drug candidate. The company's business model is focused on the discovery, development, and future commercialization of this branded pharmaceutical to treat cannabis-induced toxicity.
CTXR
Citius Pharmaceuticals
$12.63Mn
0.46
+0.00%
-66.91%
Citius Pharmaceuticals develops and markets branded prescription drugs, specifically the FDA-approved lymphoma therapy LYMPHIR. Its revenue is derived from the sales of these branded pharmaceutical products to hospitals and oncology clinics.
RKTO
2nd
Rocket One
$12.52Mn
0.54
+1.89%
-64.71%
The company is developing several small-molecule or formulation-based branded prescription drugs, including HT-001 for skin toxicities and HT-KIT for mast cell derived cancers, which fall under traditional pharmaceutical development.
BFRI
Biofrontera
$12.08Mn
0.85
+2.41%
-13.27%
Biofrontera is a pharmaceutical company that develops and markets branded prescription drugs, specifically Ameluz for the treatment of actinic keratosis. Its revenue is derived from the sale of these branded prescription dermatological products to healthcare providers and distributors.
ACTU
Actuate Therapeutics
$12.01Mn
0.50
+16.28%
-93.61%
Actuate Therapeutics is developing elraglusib, which is described as an ATP-competitive small molecule for the treatment of cancers. Because it is focused on small-molecule drug development rather than biologics, it fits the Pharmaceuticals category.
KPTI
Karyopharm Therapeutics
$10.13Mn
0.35
+12.90%
-94.12%
Karyopharm Therapeutics is a commercial-stage pharmaceutical company that develops and markets branded prescription drugs, specifically XPOVIO (selinexor), an oral small molecule inhibitor for cancer. Its primary revenue is derived from net product sales of this branded pharmaceutical in the United States.
TPST
2nd
Tempest Therapeutics
$10.07Mn
0.63
-1.56%
-94.59%
The company also advances a segment of oral small molecule inhibitors, such as amezalpat for hepatocellular carcinoma and TPST 1495 for familial adenomatous polyposis, which are branded prescription drug candidates.
TVRD
Tvardi Therapeutics
$10.04Mn
1.07
+7.00%
-83.89%
Tvardi Therapeutics is developing oral small molecule therapies, specifically TTI-101 and TTI-109, to treat inflammatory and proliferative diseases. These are branded prescription drug candidates targeting hepatocellular carcinoma and idiopathic pulmonary fibrosis, which fits the profile of a pharmaceutical company developing small-molecule branded drugs.
BLRX
2nd
BioLineRx
$8.92Mn
2.05
+0.49%
-46.61%
The company also develops small-molecule drugs, specifically GLIX1, which is described as a first-in-class oral small molecule used to induce DNA damage in glioblastoma tumors.
CURX
Curanex Pharmaceuticals
$6.85Mn
4.83
-1.43%
-63.85%
Curanex Pharmaceuticals is a developmental stage company focused on discovering and commercializing botanical drugs, such as its lead candidate Phyto N, for the treatment of inflammatory diseases. Its future revenue model is based on the sale of branded prescription pharmaceuticals to healthcare providers and specialty pharmacies.
TRAW
Traws Pharma
$6.26Mn
0.41
+2.50%
-85.51%
Traws Pharma is a biopharmaceutical company developing small-molecule drug candidates such as tivoxavir marboxil (an endonuclease inhibitor) and narazaciclib (a kinase inhibitor). These are branded prescription drug candidates targeting influenza, COVID-19, and oncology, which fits the profile of a pharmaceutical developer.
RVPH
Reviva Pharmaceuticals Holdings
$6.16Mn
0.47
+0.00%
-96.27%
Reviva Pharmaceuticals is a pharmaceutical company developing new chemical entities, such as brilaroxazine (RP5063) and RP1208, for central nervous system and cardiometabolic conditions. The company focuses on discovering and developing branded prescription drugs for psychiatric and neurologic disorders.
ALZN
2nd
Alzamend Neuro
$6.08Mn
1.26
-6.67%
-45.69%
The company is also developing AL001, an ionic cocrystal of lithium designed to treat bipolar disorder, major depressive disorder, and PTSD, which represents a branded prescription pharmaceutical approach.
INM
2nd
InMed Pharmaceuticals
$5.54Mn
1.33
+1.53%
-39.55%
InMed discovers and develops proprietary small molecule drug candidates, such as INM901 for Alzheimer's and INM089 for macular degeneration, with the intent to file new drug applications for branded prescription pharmaceuticals.
ACXP
Acurx Pharmaceuticals
$5.48Mn
1.17
+1.74%
-83.59%
Acurx Pharmaceuticals is developing a new class of small molecule antibiotics, such as ibezapolstat, to treat bacterial infections. Its revenue model is based on the future sale of these branded prescription pharmaceuticals or licensing them to larger pharmaceutical firms.
TCRT
Alaunos Therapeutics
$5.42Mn
2.18
+5.31%
-31.66%
Alaunos Therapeutics is developing orally administered small molecule therapeutics, specifically its lead candidate ALN1003, for obesity and metabolic disorders. Because it focuses on small-molecule drug discovery and development rather than biologics, it fits the Pharmaceuticals category.
PULM
Pulmatrix
$5.15Mn
1.41
+2.17%
-70.38%
Pulmatrix develops branded prescription inhaled therapeutics, such as PUR3100 for migraine and PUR1800 for COPD. These are small-molecule drug candidates designed for specific therapeutic indications, fitting the profile of a branded pharmaceutical developer.
PCSA
Processa Pharmaceuticals
$4.69Mn
1.68
+3.70%
-83.61%
Processa Pharmaceuticals focuses on developing small molecule therapies, such as NGC Cap for breast cancer and PCS12852 for gastroparesis. These are branded prescription drug candidates rather than biologics, fitting the definition of Pharmaceuticals.
QCLS
2nd
Q
$4.59Mn
0.56
+3.70%
-88.19%
The company maintains a pharmaceutical business developing branded prescription candidates, specifically Isomyosamine, a small molecule for autoimmune diseases, and Supera CBD for epilepsy and pain.
BICX
BioCorRx
$4.32Mn
0.25
+0.00%
-44.44%
The company develops and markets branded prescription drugs, specifically the FDA-approved medication Lucemyra for opioid withdrawal and the clinical-stage implantable naltrexone pellet BICX104. Revenue is generated from the sale and distribution of these pharmaceutical products.
EMMA
Emmaus Life Sciences
$4.21Mn
0.06
+0.00%
+500.00%
Emmaus Life Sciences is a commercial-stage biopharmaceutical company that markets and sells Endari®, a branded prescription-grade L-glutamine oral powder for sickle cell disease. Its primary revenue is generated from the sale of this branded pharmaceutical product in the U.S. and international markets.
ADXN
Addex Therapeutics
$3.73Mn
3.03
+14.34%
-65.05%
Addex Therapeutics is a clinical-stage pharmaceutical firm focused on the discovery and development of novel orally available small molecule drug candidates, such as dipraglurant and ADX71149. Its business model centers on developing branded prescription pharmaceuticals for indications like post-stroke traumatic brain injury recovery and chronic cough.
CALC
CalciMedica
$3.69Mn
1.08
+0.93%
-93.12%
CalciMedica is developing small molecule CRAC channel inhibitors, specifically Auxora (containing zegocractin) and CM5480. These are branded prescription drug candidates targeting inflammatory and immunologic processes, which fits the profile of a pharmaceutical company.
NYMXF
Nymox Pharmaceutical
$3.06Mn
0.03
+0.00%
-70.00%
Nymox Pharmaceutical is developing NX-1207, a branded prescription drug candidate for the treatment of benign prostatic hyperplasia and prostate cancer. The company's business model is centered on the discovery, development, and future commercialization of this branded pharmaceutical compound.
CVKD
Cadrenal Therapeutics
$3.01Mn
0.97
-4.90%
-93.10%
Cadrenal Therapeutics is a biopharmaceutical company developing branded prescription drugs, including CAD 1005 for heparin induced thrombocytopenia, tecarfarin as a vitamin K antagonist, and frunexian as a Factor XIa inhibitor. These are small-molecule therapeutic candidates intended for commercial sale to hospitals and clinicians.
CANF
Can-Fite BioPharma
$2.46Mn
1.88
-2.08%
-82.26%
Can-Fite BioPharma discovers and develops orally bioavailable small molecule drugs, such as Piclidenoson and Namodenoson, for the treatment of cancer, liver, and inflammatory diseases. Its revenue model is based on licensing these branded prescription drug candidates to pharmaceutical partners like Cipher Pharmaceuticals and Gebro Holding.
EOCN
Galmed Pharmaceuticals
$2.42Mn
2.94
-2.00%
-74.83%
Galmed Pharmaceuticals focuses on the development of Aramchol, a synthetic conjugate (small-molecule) oral SCD1 modulator for the treatment of NASH and other liver diseases. The company's revenue model is based on licensing agreements for this branded pharmaceutical candidate, such as the agreement with Samil Pharma Co. Ltd.
CASIF
CASI Pharmaceuticals
$2.06Mn
0.10
+0.00%
-94.57%
CASI Pharmaceuticals develops and commercializes branded prescription drugs for hematology, oncology, and autoimmune areas, generating revenue from products like EVOMELA and FOLOTYN. Its business model focuses on acquiring and launching innovative medicines in the China market.
OGEN
Oragenics
$1.99Mn
0.44
+2.33%
-67.65%
Oragenics is a biopharmaceutical company developing ONP 002, a synthetic neurosteroid for the treatment of mild traumatic brain injury. The company's business model focuses on the discovery and development of branded prescription pharmaceutical therapies for neurological conditions.
ENSC
Ensysce Biosciences
$1.53Mn
0.60
+7.14%
-75.71%
Ensysce Biosciences is a pharmaceutical company developing branded prescription drugs for severe pain relief, specifically focusing on opioid pain products like PF614. Its business model is centered on the research, development, and future commercialization of these proprietary branded therapeutics.
ATXI
Avenue Therapeutics
$1.42Mn
0.43
+2.38%
-39.44%
Avenue Therapeutics is a specialty pharmaceutical company developing branded prescription drugs, specifically intravenous tramadol for postoperative acute pain and ATX-04 for Pompe disease. Its business model focuses on the development and commercialization of these branded pharmaceutical candidates through regulatory pathways like the 505(b)(2) process.
PTIX
2nd
Protagenic Therapeutics, Inc.\new
$1.38Mn
0.76
-5.00%
-76.25%
The company's Phytanix Bio Programs include the development of small-molecule and synthetic assets, such as PHYX-001 (a Kv7.2/7.3 agonist) and PHYX-005 (a stilbenoid-based asset), which align with branded pharmaceutical development.
EVFM
Evofem Biosciences
$1.33Mn
0.01
+0.00%
+0.00%
Evofem Biosciences develops, manufactures, and markets branded prescription drugs, specifically PHEXX (a non-hormonal contraceptive gel) and SOLOSEC (an oral antimicrobial agent). Its revenue is derived from the sales of these branded pharmaceutical products to healthcare providers and patients.
SKVI
Skinvisible
$1.08Mn
0.20
+0.00%
-68.75%
Skinvisible develops and patents topical prescription products and delivery systems, such as Invisicare, which it licenses to pharmaceutical companies. Its revenue model is based on upfront fees and royalties from these branded pharmaceutical assets and life cycle management for drugs coming off patent.
GCAN
Trafalgar International
$1.08Mn
1.14
+0.00%
+418.18%
The company is developing and commercializing cannabinoid therapeutics for neuropsychiatric disorders such as autism, schizophrenia, Parkinson’s, and Alzheimer’s disease. It is currently advancing a therapeutic into Phase 2 clinical trials to create branded prescription drug products.
MTNB
Matinas BioPharma Holdings
$1.04Mn
2.43
-2.41%
+27.89%
Matinas BioPharma is a clinical-stage company developing MAT2203, an oral formulation of amphotericin B, which is a small-molecule branded prescription drug candidate for invasive fungal infections. The company's core business is the development of branded pharmaceuticals, as evidenced by its lead product candidate and its pursuit of licensing or sale of this specific drug asset.
CTTH
Ctt Pharmaceutical Holdings
$946.14K
0.06
+0.00%
+0.00%
The company is developing branded prescription-grade delivery systems for pharmaceuticals, specifically targeting pain management and smoking cessation. Its core business is the research and development of these branded pharmaceutical agents incorporated into dissolvable wafers.
BTAIQ
2nd
BioXcel Therapeutics
$939.15K
0.03
-25.00%
-98.88%
The company generates revenue from the sales of IGALMI®, a branded prescription drug used for the acute treatment of agitation associated with schizophrenia or bipolar disorder.
JAGX
Jaguar Health
$734.64K
4.59
+9.81%
-94.22%
Jaguar Health is a specialty pharmaceutical company that develops and markets branded prescription drugs, such as Mytesi for HIV-related diarrhea and Gelclair for oral mucositis. Its revenue is derived from the sale of these branded prescription products and licensing agreements.
SPRC
SciSparc
$730.89K
2.00
-45.65%
-94.82%
SciSparc is a clinical-stage pharmaceutical company developing branded prescription drug candidates such as SCI-110 and SCI-210 for CNS disorders like Tourette syndrome and Alzheimer's disease. Its revenue model includes potential commercialization of these drugs and licensing agreements with royalty-bearing rights, such as the SCI-160 pain program outlicensed to Polyrizon.
ZVSA
2nd
ZyVersa Therapeutics
$404.80K
0.05
+25.00%
-66.67%
The company is also developing VAR 200 (2-hydroxypropyl-beta-cyclodextrin), which is a small-molecule drug candidate for the treatment of chronic glomerular diseases like focal segmental glomerulosclerosis.
ZCMD
2nd
Zhongchao
$24.18K
1.39
+0.72%
-99.73%
The company operated the Xinjiang Pharmaceutical unit, which generated revenue by selling patented drugs.
CMND
Clearmind Medicine
$10.20K
6.42
+2.07%
-98.30%
Clearmind Medicine is a clinical-stage pharmaceutical company developing MEAI, a non-hallucinogenic molecule intended for the treatment of alcohol use disorder and obesity. The company aims to generate revenue from the sale of these branded prescription therapeutics following regulatory approval.
CDT
CDT Equity
$5.30K
0.21
-12.50%
-99.98%
CDT Equity is a pharmaceutical development company that focuses on advancing therapeutic assets like the AZD1656 glucokinase activator and AZD5904 myeloperoxidase inhibitor. Its revenue model is based on licensing these branded pharmaceutical candidates to third parties in exchange for upfront payments, milestones, and royalties.
SXTC
China SXT Pharmaceuticals
$838.32
0.07
+0.00%
-100.00%
China SXT Pharmaceutical researches, develops, manufactures, and markets branded traditional Chinese medicine products under the Suxuantang brand. Its revenue is generated from the sale of Advanced, Fine, and Regular TCMP products sold to hospitals and pharmaceutical distributors.
OCEA
2nd
Ocean Biomedical
$0.00
0.00
—
-100.00%
In addition to biologics, the company develops small-molecule therapeutic candidates, such as OCF-203 for fibrosis and ODA-579 for infectious diseases, which fall under branded pharmaceutical development.
RGBP
2nd
Regen BioPharma
$0.00
0.00
—
-100.00%
The company maintains a 'small molecule drugs' segment consisting of patented small molecules intended to activate or inhibit NR2F6 activity for cancer and autoimmune disorder treatment.